{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T21:01:53Z","timestamp":1790197313558,"version":"4.1.0"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.phrs.2026.108420","type":"journal-article","created":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T15:22:40Z","timestamp":1788016960000},"page":"108420","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Heterogeneous associations of antidiabetic medications with cancer prognosis: Evidence from 61 studies with over 1.1 million patients"],"prefix":"10.1016","volume":"232","author":[{"given":"Peng","family":"Luo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanxi","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiye","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyue","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7217-0111","authenticated-orcid":false,"given":"Jian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7560-8673","authenticated-orcid":false,"given":"Xiaobing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anqi","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2026.108420_bib1","doi-asserted-by":"crossref","unstructured":"GBD 2021 Diabetes Collaborators. Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the global burden of disease study 2021. Lancet Lond Engl 2023;402:203\u201334. .https:\/\/doi.org\/10.1016\/S0140-6736(23)01301-6.","DOI":"10.1016\/S0140-6736(23)01301-6"},{"key":"10.1016\/j.phrs.2026.108420_bib2","doi-asserted-by":"crossref","unstructured":"Bray F., Laversanne M., Sung H., Ferlay J., Siegel R.L., Soerjomataram I., et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries n.d. https:\/\/doi.org\/10.3322\/caac.21834.","DOI":"10.3322\/caac.21834"},{"key":"10.1016\/j.phrs.2026.108420_bib3","doi-asserted-by":"crossref","unstructured":"J. Pearson-Stuttard, N. Papadimitriou, G. Markozannes, S. Cividini, A. Kakourou, D. Gill, Type 2 diabetes and cancer: an umbrella review of observational and mendelian randomization studies. Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol 2021;30:1218\u20131228. https:\/\/doi.org\/10.1158\/1055-9965.EPI-20-12452021.","DOI":"10.1158\/1055-9965.EPI-20-1245"},{"key":"10.1016\/j.phrs.2026.108420_bib4","doi-asserted-by":"crossref","first-page":"g7607","DOI":"10.1136\/bmj.g7607","article-title":"Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies","volume":"350","author":"Tsilidis","year":"2015","journal-title":"BMJ"},{"key":"10.1016\/j.phrs.2026.108420_bib5","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1038\/s41575-018-0038-1","article-title":"Adiposity and gastrointestinal cancers: epidemiology, mechanisms and future directions","volume":"15","author":"Murphy","year":"2018","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.phrs.2026.108420_bib6","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.2337\/dc10-0666","article-title":"Diabetes and cancer: a consensus report","volume":"33","author":"Giovannucci","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1016\/j.phrs.2026.108420_bib7","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-73668-y","article-title":"A national observation study of cancer incidence and mortality risks in type 2 diabetes compared to the background population over time","volume":"10","author":"Bjornsdottir","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.phrs.2026.108420_bib8","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1186\/s12916-024-03430-y","article-title":"Diabetes and further risk of cancer: a nationwide population-based study","volume":"22","author":"Chang","year":"2024","journal-title":"BMC Med."},{"key":"10.1016\/j.phrs.2026.108420_bib9","first-page":"62","article-title":"Breaking boundaries: chronic diseases and the frontiers of immune microenvironments","volume":"1","author":"Li","year":"2025","journal-title":"Med. Res."},{"key":"10.1016\/j.phrs.2026.108420_bib10","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.tem.2020.05.004","article-title":"Rethinking the relationship between insulin and cancer","volume":"31","author":"Vigneri","year":"2020","journal-title":"Trends Endocrinol. Metab. TEM"},{"key":"10.1016\/j.phrs.2026.108420_bib11","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/s41568-020-0295-5","article-title":"Hyperinsulinaemia in cancer","volume":"20","author":"Gallagher","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.phrs.2026.108420_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.102062","volume":"8","author":"Silvestris","year":"2023","journal-title":"ESMO Open."},{"key":"10.1016\/j.phrs.2026.108420_bib13","doi-asserted-by":"crossref","unstructured":"Endocrinology TLD&. Diabetes and cancer in the age of multimorbidity. Lancet Diabetes Endocrinol 2026;14:1. .https:\/\/doi.org\/10.1016\/S2213-8587(25)00365-1.","DOI":"10.1016\/S2213-8587(25)00365-1"},{"key":"10.1016\/j.phrs.2026.108420_bib14","doi-asserted-by":"crossref","unstructured":"Unravelling the obesity paradox in cancer: an umbrella review of protective associations and evidence credibility across 13 malignancies. Metabolism 2026;175:156461. https:\/\/doi.org\/10.1016\/j.metabol.2025.156461.","DOI":"10.1016\/j.metabol.2025.156461"},{"key":"10.1016\/j.phrs.2026.108420_bib15","doi-asserted-by":"crossref","unstructured":"Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: systematic review and network meta-analysis. Metabolism 2025;164:156113. https:\/\/doi.org\/10.1016\/j.metabol.2024.156113.","DOI":"10.1016\/j.metabol.2024.156113"},{"key":"10.1016\/j.phrs.2026.108420_bib16","doi-asserted-by":"crossref","first-page":"302","DOI":"10.3390\/biology13050302","article-title":"Metformin: from diabetes to cancer-unveiling molecular mechanisms and therapeutic strategies","volume":"13","author":"Amengual-Cladera","year":"2024","journal-title":"Biology"},{"key":"10.1016\/j.phrs.2026.108420_bib17","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1186\/s12967-023-04263-8","article-title":"Metformin and cancer hallmarks: shedding new lights on therapeutic repurposing","volume":"21","author":"Hua","year":"2023","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.phrs.2026.108420_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2023.110621","article-title":"Sodium-glucose cotransporter-2 inhibitors and cancer outcomes: a systematic review and meta-analysis of randomized controlled trials","volume":"198","author":"Spiazzi","year":"2023","journal-title":"Diabetes Res. Clin. Pract."},{"key":"10.1016\/j.phrs.2026.108420_bib19","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s40364-025-00765-3","article-title":"Glucagon-like peptide 1 receptor agonists and cancer risk: advancing precision medicine through mechanistic understanding and clinical evidence","volume":"13","author":"Lin","year":"2025","journal-title":"Biomark. Res."},{"key":"10.1016\/j.phrs.2026.108420_bib20","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2025.2681","article-title":"GLP-1 receptor agonists and cancer risk in adults with obesity","author":"Dai","year":"2025","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.phrs.2026.108420_bib21","doi-asserted-by":"crossref","first-page":"405","DOI":"10.3389\/fonc.2020.00405","article-title":"Impact of DPP4 inhibitors in survival of patients with prostate, pancreas, and breast cancer","volume":"10","author":"Shah","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.phrs.2026.108420_bib22","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3389\/fendo.2017.00031","article-title":"PPAR-\u03b3 agonists As antineoplastic agents in cancers with dysregulated IGF axis","volume":"8","author":"Vella","year":"2017","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.phrs.2026.108420_bib23","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.3390\/app15041925","article-title":"Therapeutic potential and challenges of pioglitazone in cancer treatment","volume":"15","author":"Vasileiou","year":"2025","journal-title":"Appl. Sci."},{"key":"10.1016\/j.phrs.2026.108420_bib24","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1634\/theoncologist.2013-0111","article-title":"Metformin is associated with survival benefit in cancer patients with concurrent type 2 diabetes: a systematic review and meta-analysis","volume":"18","author":"Yin","year":"2013","journal-title":"Oncologist"},{"key":"10.1016\/j.phrs.2026.108420_bib25","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1186\/1471-2407-12-410","article-title":"The effect of metformin and thiazolidinedione use on lung cancer in diabetics","volume":"12","author":"Mazzone","year":"2012","journal-title":"BMC Cancer"},{"key":"10.1016\/j.phrs.2026.108420_bib26","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0314565","article-title":"Investigating the relationship between insulin use and all-cause mortality, breast cancer mortality, and recurrence risk in diabetic patients with breast cancer: a comprehensive systematic review and meta-analysis","volume":"19","author":"Loktionova","year":"2024","journal-title":"PLOS One"},{"key":"10.1016\/j.phrs.2026.108420_bib27","doi-asserted-by":"crossref","DOI":"10.1002\/dmrr.2823","article-title":"Type 2 diabetes, insulin treatment and prognosis of breast cancer","volume":"33","author":"Mu","year":"2017","journal-title":"Diabetes Metab. Res. Rev."},{"key":"10.1016\/j.phrs.2026.108420_bib28","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1080\/13813450903008628","article-title":"Proliferative effect of apidra (insulin glulisine), a rapid-acting insulin analogue on mammary epithelial cells","volume":"115","author":"Shukla","year":"2009","journal-title":"Arch. Physiol. Biochem."},{"key":"10.1016\/j.phrs.2026.108420_bib29","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1007\/s00125-009-1444-2","article-title":"Insulin glargine use and short-term incidence of malignancies-a population-based follow-up study in Sweden","volume":"52","author":"Jonasson","year":"2009","journal-title":"Diabetologia"},{"key":"10.1016\/j.phrs.2026.108420_bib30","doi-asserted-by":"crossref","first-page":"299","DOI":"10.2337\/dc11-1313","article-title":"Mortality after incident cancer in people with and without type 2 diabetes: impact of metformin on survival","volume":"35","author":"Currie","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.phrs.2026.108420_bib31","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.21887","article-title":"GLP-1 RA use and survival among older adults with cancer and type 2 diabetes","volume":"8","author":"Radwan","year":"2025","journal-title":"JAMA Netw. Open."},{"key":"10.1016\/j.phrs.2026.108420_bib32","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1097\/EDE.0b013e3181fe7999","article-title":"PRISMA statement","volume":"22","author":"Takkouche","year":"2011","journal-title":"Epidemiology"},{"key":"10.1016\/j.phrs.2026.108420_bib33","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis","volume":"8","author":"Tierney","year":"2007","journal-title":"Trials"},{"issue":"2","key":"10.1016\/j.phrs.2026.108420_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.craph.2025.100023","article-title":"Onlinemeta: A web server for meta-analysis based on Shiny framework","volume":"19","author":"Dai","year":"2026","journal-title":"Curr. Radiopharm."},{"key":"10.1016\/j.phrs.2026.108420_bib35","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/s41568-020-0295-5","article-title":"Hyperinsulinaemia in cancer","volume":"20","author":"Gallagher","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.phrs.2026.108420_bib36","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.jaccao.2024.01.007","article-title":"The cardioprotective and anticancer effects of SGLT2 inhibitors","volume":"6","author":"Dabour","year":"2024","journal-title":"JACC CardioOncology State---Art. Rev. JACC CardioOncology"},{"key":"10.1016\/j.phrs.2026.108420_bib37","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.trecan.2025.04.010","article-title":"Repurposing glucose-lowering drugs for cancer therapy","volume":"11","author":"Luconi","year":"2025","journal-title":"Trends Cancer"},{"key":"10.1016\/j.phrs.2026.108420_bib38","doi-asserted-by":"crossref","first-page":"S575","DOI":"10.1016\/S0168-8278(23)01374-0","article-title":"Dipeptidyl-peptidase 4 inhibitors improve survival of patients with diabetes mellitus and hepatocellular carcinoma receiving immunotherapy","volume":"78","author":"Yiu","year":"2023","journal-title":"J. Hepatol."},{"key":"10.1016\/j.phrs.2026.108420_bib39","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.927390","article-title":"Insulin-like growth factor-1 signaling in the tumor microenvironment: carcinogenesis, cancer drug resistance, and therapeutic potential","volume":"13","author":"Nwabo Kamdje","year":"2022","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.phrs.2026.108420_bib40","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/s41392-023-01451-2","article-title":"Immunosenescence: molecular mechanisms and diseases","volume":"8","author":"Liu","year":"2023","journal-title":"Signal. Transduct. Target. Ther."},{"key":"10.1016\/j.phrs.2026.108420_bib41","doi-asserted-by":"crossref","DOI":"10.1038\/s12276-025-01527-9","article-title":"Targeting immunosenescence and inflammaging: advancing longevity research","author":"Nguyen","year":"2025","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.phrs.2026.108420_bib42","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s40262-025-01494-4","article-title":"Influence of ageing on the pharmacodynamics and pharmacokinetics of chronically administered medicines in geriatric patients: a review","volume":"64","author":"Ngcobo","year":"2025","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.phrs.2026.108420_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.104511","article-title":"Targeting glucose metabolism to suppress cancer progression: prospective of anti-glycolytic cancer therapy","volume":"150","author":"Abdel-Wahab","year":"2019","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2026.108420_bib44","doi-asserted-by":"crossref","DOI":"10.1002\/smsc.202300192","article-title":"Exploiting the warburg effect: Co-delivery of metformin and FOXK2 siRNA for ovarian cancer therapy","volume":"4","author":"Zhou","year":"2024","journal-title":"Small Sci."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104366182600335X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104366182600335X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T20:08:25Z","timestamp":1790194105000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S104366182600335X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":44,"alternative-id":["S104366182600335X"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2026.108420","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Heterogeneous associations of antidiabetic medications with cancer prognosis: Evidence from 61 studies with over 1.1 million patients","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2026.108420","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"108420"}}